Journal
INTERNATIONAL JOURNAL OF STROKE
Volume 7, Issue 5, Pages 426-434Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1111/j.1747-4949.2012.00840.x
Keywords
chronic disease; functional imaging; ischemic stroke; stem cells; stroke; therapy
Categories
Funding
- ReNeuron Limited
Ask authors/readers for more resources
Stroke, for some years now the neglected major indication in the pharmaceutical development cupboard, has recently become one of the hot areas for stem cell therapy development. This is driven by better understanding of potential therapeutic opportunities both in the acute and chronic phases and the launch of a series of new early phase clinical trials in a number of countries, driven by positive data in relevant animal models. In addition, the impetus for stem cell product development is motivated by patient demand, with thousands of victims seeking unproven treatments abroad. This article looks at the many challenges facing the development of a stem cell therapy for stroke. These range from product characterization and banking, through nonclinical safety and efficacy to the regulatory requirements for starting patient trials and beyond to maximizing value from carefully designed efficacy trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available